Masato Bingo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masato Bingo has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Ei Kinai
Department of Laboratory Medicine Tokyo Medical University Tokyo Japan
4 shared publications Akito Ichiki
3 shared publications- Mihoko Yotsumoto
Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo 160-0023, Japan
3 shared publications - Ryoko Sekiya
Department of Infectious Diseases Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Bunkyo‐ku Japan
3 shared publications Ryui Miyashita
3 shared publicationsKagehiro Amano
Tokyo Med Univ Hosp, Lab Med, Tokyo, Japan
2 shared publications
Latest Publications
- 30 September 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (11)
Aspergillus tubingensis pneumonia with pulmonary oxalosis in a virologically suppressed person with HIV: A case report
- 30 September 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (11)
Aspergillus tubingensis pneumonia with pulmonary oxalosis in a virologically suppressed person with HIV: A case report
- Open Access
- 10 April 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (3)
Comparison of genotypes and phenotypes for von Willebrand factor gene variants using Japanese genome database
- 10 April 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (3)
Open AccessComparison of genotypes and phenotypes for von Willebrand factor gene variants using Japanese genome database
- Open Access
- 22 October 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (2) , 102544
Effects of switching to dolutegravir/lamivudine from tenofovir alafenamide fumarate/emtricitabine/dolutegravir or abacavir/lamivudine/dolutegravir on body weight and lipid profile in Japanese people living with HIV
- 22 October 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (2) , 102544
Open AccessEffects of switching to dolutegravir/lamivudine from tenofovir alafenamide fumarate/emtricitabine/dolutegravir or abacavir/lamivudine/dolutegravir on body weight and lipid profile in Japanese people living with HIV
- Open Access
- 10 August 2024
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 11 (3) , 541-552
Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A
Background Treatment for haemophilia A has expanded from plasma-derived factor VIII (pdFVIII) and standard half-life (SHL) recombinant FVIII (rFVIII) to extended half-life (EHL) rFVIII and non-factor products that mimic FVIII activity. Objective To determine amounts of clotting factor concentrates (CFCs) and emicizumab dispensed and associated healthcare expenditures in Japanese patients with haemophilia A. Methods This retrospective, non-interventional, observational study analysed data from 2016 to 2020 from a large-scale, hospital-based administrative database. Patients had haemophilia A without inhibitors and ≥ 2 prescriptions of the same CFC or emicizumab. Results In total, 974 patients with haemophilia A (median age, 30.0 years; median follow-up, 3.7 years) were included. Outpatient use of EHL rFVIII and emicizumab increased, although pdFVIII/SHL rFVIII were still used over the study. Median annual total healthcare expenditures/patient increased from ¥9,200,230 in 2016 to ¥19,748,221 in 2020. Overall, the median annual drug expenditure/patient increased from ¥8,723,120 in 2016 to ¥18,051,689 in 2020. Drug expenditure was highest with emicizumab, with an increase in median annual expenditure/patient from 2018 (n = 4, ¥26,030,206) to 2020 (n = 107, ¥45,430,408). Overall, 233 patients (23.9%) switched from an SHL to an EHL product. Although amounts of FVIII prescribed increased in the 3 months after switching, overall, there was no noticeable difference before and after switching. Median total healthcare and FVIII product expenditures increased following switching. Conclusions Prescribing of EHL products increased over the study and healthcare expenditures increased for patients who switched from SHL to EHL rFVIII products.
- 10 August 2024
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 11 (3) , 541-552
Open AccessReal-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A
Background Treatment for haemophilia A has expanded from plasma-derived factor VIII (pdFVIII) and standard half-life (SHL) recombinant FVIII (rFVIII) to extended half-life (EHL) rFVIII and non-factor products that mimic FVIII activity. Objective To determine amounts of clotting factor concentrates (CFCs) and emicizumab dispensed and associated healthcare expenditures in Japanese patients with haemophilia A. Methods This retrospective, non-interventional, observational study analysed data from 2016 to 2020 from a large-scale, hospital-based administrative database. Patients had haemophilia A without inhibitors and ≥ 2 prescriptions of the same CFC or emicizumab. Results In total, 974 patients with haemophilia A (median age, 30.0 years; median follow-up, 3.7 years) were included. Outpatient use of EHL rFVIII and emicizumab increased, although pdFVIII/SHL rFVIII were still used over the study. Median annual total healthcare expenditures/patient increased from ¥9,200,230 in 2016 to ¥19,748,221 in 2020. Overall, the median annual drug expenditure/patient increased from ¥8,723,120 in 2016 to ¥18,051,689 in 2020. Drug expenditure was highest with emicizumab, with an increase in median annual expenditure/patient from 2018 (n = 4, ¥26,030,206) to 2020 (n = 107, ¥45,430,408). Overall, 233 patients (23.9%) switched from an SHL to an EHL product. Although amounts of FVIII prescribed increased in the 3 months after switching, overall, there was no noticeable difference before and after switching. Median total healthcare and FVIII product expenditures increased following switching. Conclusions Prescribing of EHL products increased over the study and healthcare expenditures increased for patients who switched from SHL to EHL rFVIII products.
- Open Access
- 17 October 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (7) , 102233
Trisomy X conferring moderate hemophilia A by extremely skewed X-chromosome inactivation
- 17 October 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (7) , 102233
Open AccessTrisomy X conferring moderate hemophilia A by extremely skewed X-chromosome inactivation
- Open Access
- 29 October 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (2) , 171-178
Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV
- 29 October 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (2) , 171-178
Open AccessYoung age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV
- Open Access
- 1 January 2022
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 33 (1) , 53-56
COVID-19 vaccination for people with bleeding disorders
- 1 January 2022
- Published by Japanese Society on Thrombosis and Hemostasis in Japanese Journal of Thrombosis and Hemostasis
- Vol. 33 (1) , 53-56
Open AccessCOVID-19 vaccination for people with bleeding disorders